Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients

International Journal of Cancer

Volumn 136, Issue 10, 2015, Pages 2352-2360

  Jiang, Huanhuan ^a,b,c   Gebhardt, Christoffer ^a,b   Umansky, Ludmila ^a   Beckhove, Philipp ^a   Schulze, Torsten J ^d   Utikal, Jochen ^a,b   Umansky, Viktor ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

chronic inflammatory factors; immunosuppression; melanoma; myeloid derived suppressor cells; regulatory T cells

Indexed keywords

ALPHA INTERFERON; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EOTAXIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; IPILIMUMAB; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; CXCL10 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL ISOLATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; VERY ELDERLY; BLOOD; BONE MARROW CELL; DISEASE COURSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CHEMOKINE CXCL10; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-1BETA; MALE; MELANOMA; MIDDLE AGED; MYELOID CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 84924311399     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29297     Document Type: Article

References (49)

1. Erdmann F, Lortet-Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer 2013; 132: 385-400.
2. Pflugfelder A, Kochs C, Blum A, et al. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges 2013; Suppl 6: 1-116.
3. Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
4. Gogas H, Polyzos A, Kirkwood J,. Immunotherapy for advanced melanoma: fulfilling the promise. Cancer Treat Rev 2013; 39: 879-85.
5. Ott PA, Hodi FS, Robert C,. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19: 5300-9.
6. Gajewski TF, Woo SR, Zha Y, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013; 25: 268-76.
7. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V,. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-68.
8. Umansky V, Sevko A,. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22: 319-26.
9. Jacobs JF, Nierkens S, Figdor CG, et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012; 13: e32-42.
10. Tanchot C, Terme M, Pere H, et al. Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron 2013; 6: 147-57.
11. Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22: 238-44.
12. Condamine T, Gabrilovich DI,. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32: 19-25.
13. Poschke I, Mougiakakos D, Hansson J, et al. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-45.
14. Solito S, Marigo I, Pinton L, et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319: 47-65.
15. Poschke I, Kiessling R,. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012; 144: 250-68.
16. Filipazzi P, Huber V, Rivoltini L,. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61: 255-63.
17. Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of advanced melanoma patients: comparison with regulatory T cells and NY-ESO-1- or Melan-A-specific T cells. Clin Cancer Res 2014; 20: 1601-9.
18. Ostrand-Rosenberg S,. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-1600.
19. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nature Rev Immunol 2010; 10: 490-500.
20. Vignali DA, Collison LW, Workman CJ,. How regulatory T cells work. Nature Rev Immunol 2008; 8: 523-32.
21. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
22. Coussens LM, Zitvogel L, Palucka AK,. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286-91.
23. Kanterman J, Sade-Feldman M, Baniyash M,. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 2012; 22: 307-18.
24. Ostrand-Rosenberg S, Sinha P,. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-506.
25. Navarini-Meury AA, Conrad C,. Melanoma and innate immunity-active inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol 2009; 19: 84-91.
26. Allavena P, Germano G, Marchesi F, et al. Chemokines in cancer related inflammation. Exp Cell Res 2011; 317: 664-73.
27. Danesh A, Inglis HC, Jackman RP, et al. Exosomes from RBC units bind to monocytes and induce pro-inflammatory cytokines, boosting T cell responses in vitro. Blood 2014; 123: 687-96.
28. Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 2011; 108: 17111-6.
29. Ascierto PA, Napolitano M, Celentano E, et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010; 8: 76.
30. Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013; 133: 1653-63.
31. Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211: 781-90.
32. Ilkovitch D, Lopez DM,. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 2009; 69: 5514-21.
33. Balkwill FR, Mantovani A,. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012; 22: 33-40.
34. Hussain SP, Harris CC,. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-80.
35. Kim JW, Koh Y, Kim DW, et al. Clinical implications of VEGF, TGF-beta1, and IL-1beta in patients with advanced non-small cell lung cancer. Cancer Res Treat 2013; 45: 325-33.
36. Huang Q, Lan F, Wang X, et al. IL-1beta-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer 2014; 13: 18.
37. Dinarello CA,. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
38. Apte RN, Voronov E,. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 2008; 222: 222-41.
39. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14: 408-19.
40. Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-13.
41. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95: 7556-61.
42. Zaidi MR, Merlino G,. The two faces of interferon-γ in cancer. Clin Cancer Res 2011; 17: 6118-24.
43. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5: 200ra116.
44. Richmond A, Yang J, Su Y,. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009; 22: 175-86.
45. Lo BK, Yu M, Zloty D, et al. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 2010; 176: 2435-46.
46. Murakami T, Kawada K, Iwamoto M, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer 2013; 132: 276-87.
47. Harikumar KB, Yester JW, Surace MJ, et al. K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat Immunol 2014; 15: 231-8.
48. Jordan KR, Amaria RN, Ramirez O, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother 2013; 62: 1711-22.
49. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009; 15: 2166-73.